» Articles » PMID: 32285199

Human Genetic Basis of Fulminant Viral Hepatitis

Overview
Journal Hum Genet
Specialty Genetics
Date 2020 Apr 15
PMID 32285199
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In rare cases, hepatitis A virus (HAV) and hepatitis B virus (HBV) can cause fulminant viral hepatitis (FVH), characterized by massive hepatocyte necrosis and an inflammatory infiltrate. Other viral etiologies of FVH are rarer. FVH is life-threatening, but the patients are typically otherwise healthy, and normally resistant to other microbes. Only a small minority of infected individuals develop FVH, and this is the key issue to be addressed for this disease. In mice, mouse hepatitis virus 3 (MHV3) infection is the main model for dissecting FVH pathogenesis. Susceptibility to MHV3 differs between genetic backgrounds, with high and low mortality in C57BL6 and A/J mice, respectively. FVH pathogenesis in mice is related to uncontrolled inflammation and fibrinogen deposition. In humans, FVH is typically sporadic, but rare familial forms also exist, suggesting that there may be causal monogenic inborn errors. A recent study reported a single-gene inborn error of human immunity underlying FVH. A patient with autosomal recessive complete IL-18BP deficiency was shown to have FVH following HAV infection. The mechanism probably involves enhanced IL-18- and IFN-γ-dependent killing of hepatocytes by NK and CD8 T cytotoxic cells. Proof-of-principle that FVH can be genetic is important clinically, for the affected patients and their families, and immunologically, for the study of immunity to viruses in the liver. Moreover, the FVH-causing IL18BP genotype suggests that excessive IL-18 immunity may be a general mechanism underlying FVH, perhaps through the enhancement of IFN-γ immunity.

Citing Articles

Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population.

Liao T, Xia M, Hayashi P, Pan B, Aithal G, Lucena M Liver Int. 2025; 45(2):e70011.

PMID: 39868816 PMC: 11850085. DOI: 10.1111/liv.70011.


The monogenic landscape of human infectious diseases.

Boisson-Dupuis S, Bastard P, Beziat V, Bustamante J, Cobat A, Jouanguy E J Allergy Clin Immunol. 2024; 155(3):768-783.

PMID: 39724971 PMC: 11875930. DOI: 10.1016/j.jaci.2024.12.1078.


Hepatitis A virus infection.

Van Damme P, Pinto R, Feng Z, Cui F, Gentile A, Shouval D Nat Rev Dis Primers. 2023; 9(1):51.

PMID: 37770459 DOI: 10.1038/s41572-023-00461-2.


Future directions in acute liver failure.

Stravitz R, Fontana R, Karvellas C, Durkalski V, McGuire B, Rule J Hepatology. 2023; 78(4):1266-1289.

PMID: 37183883 PMC: 10521792. DOI: 10.1097/HEP.0000000000000458.


Autosomal dominant chronic mucocutaneous candidiasis with STAT1 mutation can be associated with chronic active hepatitis: A case report.

Liu L, Huang Y, Liao Y, Shu S Front Pediatr. 2023; 10:990729.

PMID: 36683786 PMC: 9852885. DOI: 10.3389/fped.2022.990729.


References
1.
Dindzans V, Skamene E, Levy G . Susceptibility/resistance to mouse hepatitis virus strain 3 and macrophage procoagulant activity are genetically linked and controlled by two non-H-2-linked genes. J Immunol. 1986; 137(7):2355-60. View

2.
OTH D, DUPUY J . Genetic study of mouse sensitivity to MHV3 infection: influence of the H-2 complex. J Immunol. 1979; 122(4):1359-62. View

3.
Latour S, Fischer A . Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Immunol Rev. 2019; 291(1):174-189. DOI: 10.1111/imr.12791. View

4.
Bleau C, Burnette M, Filliol A, Piquet-Pellorce C, Samson M, Lamontagne L . Toll-like receptor-2 exacerbates murine acute viral hepatitis. Immunology. 2016; 149(2):204-24. PMC: 5011685. DOI: 10.1111/imm.12627. View

5.
Fingerote R, Abecassis M, Phillips M, Rao Y, Cole E, Leibowitz J . Loss of resistance to murine hepatitis virus strain 3 infection after treatment with corticosteroids is associated with induction of macrophage procoagulant activity. J Virol. 1996; 70(7):4275-82. PMC: 190359. DOI: 10.1128/JVI.70.7.4275-4282.1996. View